Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is expected to see continued success with its currently marketed drug Korlym, as well as its newly approved drug Lifyorli, which has already shown strong early adoption among physicians and received positive reviews from the National Comprehensive Cancer Network. The company's pipeline also holds potential for future growth and expansion, making it a strong investment opportunity with a projected price target of $95 per diluted share in the next 12 months. The recent resubmission announcement for relacorilant NDA also provides visibility on a near-term regulatory pathway and potential second approval for the drug by YE 2026, further strengthening the company's outlook and potential for long-term success.

Corcept Therapeutics is expected to see an increase in revenues due to the launch of Lifyorli and record starts of patients on Korlym, leading to a raised revenue guidance of $1B at the midpoint for FY2026. Despite reporting lower-than-expected sales for 1Q26, the company expects to return to profitability in 2Q26 and has a strong cash position with $338M in cash and marketable securities. However, the company's reliance on a limited number of products and the risk of clinical trial failures for its pipeline compounds may pose challenges to sustained profitability in the long term.